Global T-Cell Lymphoma Market & Clinical Pipeline Insight

Description: Immune system consists of various cells that impart resistance to body against foreign entities. They also prevent the development of aberrant cells in the body to maintain its normal functioning. However, it has been noted that these cells are also liable for deterioration leading to diseases development. For instance, T-cell lymphoma is cancer causing unrestricted growth of T-cells leading to impaired immune system. Investigators have identified different T-cell malignancies that cause high morbidity and mortality. As a result, several cancer therapeutics have been developed in past years to prevent T-cell lymphoma proliferation and progression.

T-cell lymphoma is divided into several disease segments based on their pathophysiology that causes difficulty in identification and treatment. Most of the therapeutics have been developed for the Peripheral T-Cell Lymphoma (PTCL) and Cutaneous T-cell Lymphoma (CTCL) which affects blood and skin, respectively. Other subcategories of T-cell lymphoma are largely untouched due to which large unmet necessities could be observed. For instance, Adult T-cell lymphoma is found in 2%-5% patients suffering from Human T-Lymphotropic Viruses, type I (HTLV-1) infection. Generally chemotherapeutics approaches are used which have modest safety and efficacy profiles. As a result, appropriate therapeutics is not available leading to high unmet medical necessities giving emphasis on development of innovative modalities for T-cell lymphoma treatment.

With time, new modalities are expected to be developed as underlying principles behind T-cell lymphoma would be deciphered. For instance, investigators developed extracorporeal photopheresis as an advanced method that could improve survival in patients. Low toxicity and activation of treatment on demand are among one of the most sought features. This procedure could also be used with other therapeutics to achieve better pharmacological effects. Despite these benefits, its utility is limited because of special procedure requiring patients to stay in hospital for T-cell lymphoma treatment. This scenario indicates that more research and development is required for new and improved T-cell lymphoma therapeutics. Some of the progress has been made by developing immunotoxin, HDAC inhibitors, monoclonal antibodies and other investigational therapeutics.

Technological advancements are expected to help the investigators to develop better therapeutics and increase the discovery rates. Increased investments in research and development are expected to help in development of better therapeutic with superior pharmacological and commercialization potential. They are expected to offer severe competition to existing therapeutics due to which more revenues are expected to be generated. Lots of opportunity are available as myriad of candidates with different biological properties are under T-cell lymphoma clinical trials. Cancer market is expected to witness introduction of several innovative products which will help the pharmaceutical companies to generate significant revenues. These products are at different stages of clinical trials due to which they would take some time before entering in global market. In this way, future T-cell lymphoma therapeutics looks optimistic due to their superior pharmacological profiles.

“Global T-Cell Lymphoma Market & Clinical Pipeline Insight” Report Highlight:

- Mechanism of T-Cell Lymphoma Therapeutics
- T-Cell Lymphoma Drug Market Overview
- T-Cell Lymphoma Drug Clinical Pipeline By Company & Phase
- T-Cell Lymphoma Drug Clinical Pipeline By Peripheral & Cutaneous T-cell Lymphoma
- T-Cell Lymphoma Drug Clinical Pipeline: 24 Drugs
- Orphan Designated T-Cell Lymphoma Drugs: 22 Drugs
- Marketed T-Cell Lymphoma Drug Clinical Insight
- Marketed T-Cell Lymphoma Drugs: 15 Drugs
- T-Cell Lymphoma Drug Market Future Prospects

Contents:

1. T-Cell Lymphoma Market Analysis
2. Mechanism of T-Cell Lymphoma Therapeutics
3. T-Cell Lymphoma Drug Market Overview
3.1 Current Market Scenario
3.2 T Cell Lymphoma Clinical Pipeline Overview

4. T-Cell Lymphoma Drug Market Dynamics
4.1 Favorable Market Parameters
4.2 Commercialization Challenges

5. T-Cell Lymphoma Drug Market Future Prospects

6. T Cell Lymphoma Drug Clinical Pipeline By Company & Phase
6.1 Research
6.2 Preclinical
6.3 Clinical
6.4 Phase-I
6.5 Phase-I/II
6.6 Phase-II
6.7 Phase-II/III
6.8 Phase-III

7. Marketed T Cell Lymphoma Drug Clinical Insight
7.1 Belinostat (Beleodaq)
7.2 Denileukin Diftitox (ONTAK)
7.3 Mogamulizumab (Poteligeo)
7.4 Brentuximab Vedotin (Adcetris)
7.5 Pralatrexate (Difolta/Folotyn)
7.6 Interferon gamma 1a Biosimilar (Imunomax-?)
7.7 Nelarabine (Arranon/Atriance)
7.8 Vorinostat (Zolinza)
7.9 Romidepsin (Istodax)
7.10 Bexarotene Topical (Targretin Gel)
7.11 Bexarotene Oral (Targretin Oral)
7.12 Chlormethine (Ledaga/Valchlor)
7.13 Methoxsalen Solution (UVADEX)
7.14 Mogamulizumab Companion Diagnostics (Poteligeo Test FCM/IHC)
7.15 Interferon alpha-2a (Roferon-A)

8. Discontinued & No Development Reported in T-Cell Lymphoma Drug in Clinical Pipeline
8.1 Discontinued
8.2 No Development Reported

9. Competitive Landscape
9.1 Actelion Pharmaceuticals
9.2 Allos Therapeutics
9.3 Astellas Pharma
9.4 BioCryst Pharmaceuticals
9.5 Bristol-Myers Squibb
9.6 Chipscreen Biosciences
9.7 Celgene Corporation
9.8 Eisai
9.9 Genmab
9.10 Galderma
9.11 Inovio Pharmaceuticals
9.12 Johnson & Johnson Pharmaceutical Research & Development
9.13 Karyopharm Therapeutics
9.14 Kyowa Hakko Kirin
9.15 Nippon Kayaku
9.16 Novartis
9.17 Neumedicines
9.18 Onyx Pharmaceuticals
9.19 Roche
9.20 Seattle Genetics
9.21 Shionogi
9.22 Soligenix
9.23 TetraLogic Pharmaceuticals
9.24 ZIOPHARM Oncology

List of Figures:
Figure 1-1: Main Types of Blood Cancer
Figure 1-2: Types of White Blood Cells (WBC)
Figure 1-3: Types of Lymphoma
Figure 1-4: Major Type of T-Cell Lymphoma
Figure 1-5: Type of Anaplastic Large Cell Lymphoma
Figure 1-6: Type of Uncommon T-Cell Lymphomas
Figure 2-1: Extracorporeal Photopheresis (ECPP)
Figure 2-2: Mechanism of Bexarotene
Figure 2-3: Mechanism of Pralatrexate
Figure 2-4: Mechanism of Vorinostat
Figure 2-5: Mechanism of Denileukin Diftitox
Figure 2-6: Mechanism of Romidepsin
Figure 2-7: Mechanism of Alemtuzumab
Figure 3-1: T-Cell Lymphoma Pipeline by Phase(%), 2016
Figure 3-2: T-Cell Lymphoma Pipeline by Phase(Numbers), 2016
Figure 3-3: T-Cell Lymphoma Pipeline by Phase (%), 2016
Figure 3-4: T-Cell Lymphoma Pipeline by Phase (Numbers), 2016
Figure 4-1: T-Cell Lymphoma Drug Market Favorable Parameters
Figure 4-1: T-Cell Lymphoma Drug Market Commercialization Challenges

List of Tables:
Table 1-1: Staging of T-Cell Lymphoma

Ordering:
Order Online - [http://www.researchandmarkets.com/reports/3626246/](http://www.researchandmarkets.com/reports/3626246/)
Order by Fax - using the form below
Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Global T-Cell Lymphoma Market & Clinical Pipeline Insight
Web Address: http://www.researchandmarkets.com/reports/3626246/
Office Code: SCPLJF5B

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) -</td>
<td>USD 1800</td>
</tr>
<tr>
<td>Single User:</td>
<td></td>
</tr>
<tr>
<td>Hard Copy:</td>
<td>USD 2400 + USD 57</td>
</tr>
<tr>
<td></td>
<td>Shipping/Handling</td>
</tr>
<tr>
<td>CD-ROM:</td>
<td>USD 2400 + USD 57</td>
</tr>
<tr>
<td></td>
<td>Shipping/Handling</td>
</tr>
<tr>
<td>Electronic (PDF) -</td>
<td>USD 3600</td>
</tr>
<tr>
<td>Enterprisewide:</td>
<td></td>
</tr>
</tbody>
</table>

* Shipping/Handling is only charged once per order.

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: Mr □ Mrs □ Dr □ Miss □ Ms □ Prof □
First Name: ___________________________ Last Name: ___________________________
Email Address: * ____________________
Job Title: ___________________________
Organisation: _______________________
Address: ___________________________
City: _______________________________
Postal / Zip Code: ___________________
Country: ___________________________
Phone Number: ______________________
Fax Number: _________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: ____________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World